Trending Topics

 

Check out the latest cancer-related news and also see who is readily available to offer reliable information, expert commentary, and reaction to today's headlines.
Contact a media coordinator

A new drug is being shown to extend the lives of patients with advanced soft tissue sarcoma by almost a year. The results of a multicenter phase II trial evaluating the efficacy and safety of olaratumab in combination with doxorubicin chemotherapy was published in The Lancet on June 9. William Tap, MD, Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center (MSK), served as corresponding author on this study, which met its primary endpoint of progression-free survival and showed a statistically significant improvement in overall survival. To arrange an interview with Dr. Tap, please email mcnamarn@mskcc.org.
Friday, June 10, 2016
 
MSK researchers are presenting nearly 120 studies at the 2016 Annual Meeting of the American Society of Clinical Oncology.
Friday, June 3, 2016
 
Vice President Joseph Biden visited Memorial Sloan Kettering Cancer Center (MSK) for a roundtable discussion with MSK experts and members of the cancer community. The candid conversation, inspired by the “moonshot” initiative announced by President Obama, was led by Craig Thompson, MD, President and CEO of MSK. MSK’s Carol Brown, MD, Ross Levine, MD, and Robert Sidlow, MD, were also active participants in the discussion. For more information about the event or to request an interview with a MSK roundtable participant, please e-mail mediastaff@mskcc.org.
Thursday, May 26, 2016
 
See all trending topics
 

Press Releases

 
Men with metastatic prostate cancer should be considered for germline genetic testing of DNA repair genes, regardless of age or family history, according to a team of researchers from Memorial Sloan Kettering Cancer Center (MSK), Fred Hutchinson Cancer Research Center, Dana-Farber Cancer Institute, University of Washington School of Medicine, University of Michigan, and the Institute of Cancer Research Royal Marsden Hospital.
Wednesday, July 6, 2016
 
Memorial Sloan Kettering Cancer Center (MSK) molecular pharmacologist Daniel Heller, PhD, and colleagues have identified a new strategy to target drugs specifically to cancer sites, including metastatic tumors. The approach involves nanoparticles designed to mimic a mechanism that tumors themselves use to metastasize throughout the body. This work, which will be featured on the cover of the June 29 issue of Science Translational Medicine, was applicable across a wide range of tumor and drug types and can potentially be applied to other conditions including vascular and autoimmune diseases.
Wednesday, June 29, 2016
 
Andrew L. Kung, MD, PhD, has been named the new Chairman of the Department of Pediatrics at Memorial Sloan Kettering Cancer Center (MSK). An accomplished physician, researcher, leader, and mentor, Dr. Kung most recently served as the Chief of the Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation at New York-Presbyterian/Morgan Stanley Children’s Hospital and Columbia University Medical Center (CUMC). Dr. Kung formally assumes his new role as Richard J. O’Reilly, MD, steps down as Chairman after more than 30 years.
Monday, June 20, 2016
 
See all press releases
 

On Our Blog

 
Q & A
Learn why MSK was ranked one of the very best hospitals for gynecology in the country by U.S. News & World Report.
Tuesday, August 23, 2016
 
Q & A
Learn why MSK’s outstanding care for prostate, bladder, kidney, and testicular cancers resulted in U.S. News naming it one of the best hospitals for urology.
Thursday, August 18, 2016
 
FEATURE
Discover how microbiome research is revealing the role that bacteria play in cancer treatment.
Thursday, August 11, 2016
 
See all blog posts
 

Media Coverage

 
Critical Care physician Neil Halpern was interviewed about his commentary that was published in JAMA Internal Medicine in HealthDay News
Monday, August 8, 2016
 
Immunologist Jedd Wolchok and a patient were featured in a special feature in the New York Daily News about advances in immunotherapy. 
Tuesday, August 2, 2016
 
Immunologist Michel Sadelain was profiled in a special New York Times story about CART therapy. 
Monday, August 1, 2016
 
See all media coverage
 

If you wish to contact MSK about a marketing or advertising related opportunity, or are looking for additional information about our ad campaign, please email us at marketing@mskcc.org.

For Journalists

Jeanne D'Agostino
Director, Media and Public Relations
 
Emily O'Donnell
Senior Communications Associate, Department of Surgery
 
Courtney Nowak
Senior Media Relations Associate
 
Caitlin Hool
Senior Media Associate
 
Nicole H. McNamara
Senior Media Relations Associate
 
Rebecca Williams
Media Associate
 
For press inquiries, our Media Staff are available by calling 646-227-3573 or by dialing the numbers above. Our office hours are Monday - Friday, 9:00 AM to 5:00 PM.
 
After hours, please contact the hospital's page operator at 212-639-7900 and ask for the Public Affairs representative on-call.

Live and Remote Broadcast Capabilities

Our experts can offer live broadcast interviews using the on-site studio system. To book an expert interview using our on-site broadcast studio contact our Media Staff.

Subscribe to the News@MSKCC newsletter

Our email newsletter for journalists offers the latest advances in cancer research and treatment, including story ideas, institutional milestones and plans, and newsworthy staff accomplishments.

Sign up

Unsubscribe »